



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13296

**Title:** Micro RNAs (miRNAs) in the development of non-alcoholic fatty liver disease (NAFLD).

**Reviewer code:** 02446726

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-08-17 20:31

**Date reviewed:** 2014-08-18 22:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

Minor points: 1. the authors provide a nice overview on all kinds of studies that were done to study miRNAs in the setting of NAFLD. (in vitro, in vivo, human tissue, human body fluids etc.). Also, they make a cross validation of all these studies at the end of their manuscript. Surprisingly, the data derived from all these different studies seem to differ considerably. A real overlap of data is not evident. Here, I think, the authors should extent their discussion on cross- validation and try and find a plausible reason for these discrepancies and also discuss the value of all these studies in front of the background of all these different results. 2. The authors should provide the full name of NASH (non- alcoholic steatohepatitis) prios to the use of the abbreviation in their manuscript.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13296

**Title:** Micro RNAs (miRNAs) in the development of non-alcoholic fatty liver disease (NAFLD).

**Reviewer code:** 02883333

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-08-17 20:31

**Date reviewed:** 2014-09-15 22:08

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

The authors performed a review about roles of miRNAs in NAFLD. I thought an interesting topic. In my opinion, your work is accepted for publication in WJH. However, I suggest the following minor corrections: 1. Introduction: - 3rd paragraph, line 7: today, there are more than 2500 miRNAs encoded by human genes (see <http://www.mirbase.org/cgi-bin/browse.pl>) 2. In vitro studies: - 2nd paragraph, line 15: change the word 'miR122' by 'miR-122' 3. In vivo studies: - 1st paragraph line 6: remove space in 'miR-200a' - 6th paragraph line 4: change the word 'then' by 'than' 4. Huma studies: - 1st paragraph line 15: change the word 'miR122' by 'miR-122' - 2nd paragraph line 2: remove the word 'RNA'